Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Hedge Funds Make Big After Regeneron $REGN Gets FDA OK for Eylea

Regeneron Pharmaceuticals Inc.’s (REGN) shares rose 13.73% in trading on Monday after U.S. regulators approved its “drug Eylea to treat a leading cause of blindness in the elderly, handing the company a second product to sell and inserting a market challenger to Roche Holding AG (RHHBY, ROG.VX),” reports the Wall Street Journal. “Shares in Regeneron were halted before the news. The stock closed Friday down 2.6% at $49.81.” REGN was trading at $56.65 at 1:40pm EST Monday.

Leonard S. Schleifer, Regeneron Chief Executive, said Friday that REGN, “planned to make Eylea available to patients ‘within the next few days’ after the U.S. Food and Drug Administration approved it to treat wet age-related macular degeneration.”

Chuck Royce

The following hedge funds made the most on the news:

1. Qvt Financial – Daniel Gold: Gained $2.1 million

2. Royce & Associates – Chuck Royce: Gained $684,000

3. Orbimed Advisors – Samuel Isaly: Gained $527,000

4. Highbridge Capital Management – Glenn Russell Dubin: Gained $372,000

5. D E Shaw – D. E. Shaw: Gained $236,000

6. Hbk Investments – David Costen Haley: Gained $196,000

7. Sac Capital Advisors – Steven Cohen: Gained $107,000

8. Millennium Management – Israel Englander: Gained $90,000

9. Aqr Capital Management – Cliff Asness: Gained $44,000

10. Citadel Investment Group – Ken Griffin: Gained $3,300

DISCLAIMER: These calculations assume that these hedge funds did not increase or reduce their stock positions in REGN since the end of June. We did not take into account their option positions.

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!